Khambatta Securities' research report on Aurobindo Pharma
Aurobindo‟s revenues grew remained flat q-o-q and y-o-y at Rs 37,008 mn in 1Q FY18 falling short of our expectations. Revenue growth was dampened by poor offtake in ARV and API business during the quarter. API business was negatively impacted by destocking in lieu of GST implementation during the quarter.
Outlook
we arrive at a share price of Rs 800, generating a 16.7% upside potential in the medium term. Hence, we reiterate our “Strong Buy” rating for Aurobindo Pharma common stock.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
Read More
